A Phase 1 interventional study of Oral Fosmanogepix and IV Fosmanogepix in Healthy, sponsored by Basilea Pharmaceutica. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to investigate the pharmacokinetics and safety of the investigational drug fosmanogepix including its active moiety manogepix following a single dose and multiple doses (by intravenous infusion (IV) or orally) in healthy Chinese adults.
The study consisted of 2 consecutive Parts (Part-1, single-dose part followed by Part-2, multiple-dose part) including a total of 54 subjects (32 subjects in Part-1 and 22 subjects in PART-2) randomized.
Part-1 duration including screening period was up to 64 days including 4 visits at the clinical site and Part-2 duration including screening period was up to 70 days including 5 visits at the clinical site. The study included a total of 4 study sub-groups (Cohorts 1-4) in which fosmanogepix or placebo was administered in different strengths orally or IV.
Subjects were enrolled and randomly assigned to study drug.
During the study, serial blood samples were collected to understand how fosmanogepix was changed and eliminated from the body.
The primary objective of PART-1 (Single-dose) was to evaluate the pharmacokinetic (PK) profile of manogepix (active moiety of fosmanogepix) after single dose administration in healthy adult Chinese subjects.
The primary objective of PART-2 (Multiple-dose) was to evaluate the PK profile of manogepix (active moiety of fosmanogepix) after repeated doses in healthy adult Chinese subjects.
All data analyses are descriptive (no statistical analysis is provided).
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main criteria for inclusion and exclusion:
Main exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received fosmanogepix or placebo by oral administration
Drug: Oral Fosmanogepix · Drug: oral placebo
Subjects received fosmanogepix or placebo by IV infusion
Drug: IV Fosmanogepix · Drug: IV placebo
Subjects received fosmanogepix or placebo as an IV infusion twice 12 hours apart on Day 1 followed by a maintenance daily dose of fosmanogepix or placebo via IV infusion from Day 2 to Day 7
Drug: IV Fosmanogepix · Drug: IV placebo
The subjects received fosmanogepix or placebo as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7.
Drug: Oral Fosmanogepix · Drug: IV Fosmanogepix · Drug: IV placebo · Drug: oral placebo
Oral Tablet
IV infusion
Matching IV placebo
Matching oral placebo
Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-1
Pharmacokinetic (PK) parameter Cmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-1
PK parameter Tmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Area Under the Plasma Concentration vs. Time Curve for 0-24 Hours (AUC24) of Manogepix in Part-1
PK parameter AUC 24 for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Manogepix in Part-1
PK parameter AUClast for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Manogepix in Part-1
PK parameter AUC (0 - ∞) for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-2
PK parameter Cmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7
Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-2
PK parameter Tmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7
Area Under the Concentration-time Curve at Steady State Over the Dosing Interval Tau (AUCtau) of Manogepix in Part-2
PK parameter AUCtau after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7
Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7
Fraction of Unbound Manogepix in Plasma in Part 1
The fraction of unbound manogepix has been assessed after single dose administration (oral / IV)
Time frame: pre-dose and 3 hours postdose
Number of Subjects With Treatment-emergent AE (TEAE) in Part-1
A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug
Time frame: Up to 36 days
Number of Subjects With TEAE in Part-2
A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug
Time frame: Up to 42 days
The study was conducted at one site in China
| Milestone | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 8 | 9 | 9 | 4 |
| Completed | 6 | 6 | 6 | 6 | 8 | 7 | 8 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Did not receive study drug due to safety finding pre-dose | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
Pharmacokinetic (PK) parameter Cmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
| ng/mL | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-1 | 5750 ± 39.5 | 10865 ± 12.9 | 8343 ± 31.1 | 13874 ± 18.0 |
PK parameter Tmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
| hour | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) |
|---|---|---|---|---|
| Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-1 | 2.50 (2.00 to 3.00) | 3.00 (2.00 to 4.00) | 2.96 (2.85 to 3.05) | 2.99 (2.87 to 3.05) |
PK parameter AUC 24 for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
| h*ng/mL | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) |
|---|---|---|---|---|
| Area Under the Plasma Concentration vs. Time Curve for 0-24 Hours (AUC24) of Manogepix in Part-1 | 49823 ± 17.3 | 89822 ± 25.3 | 76270 ± 32.3 | 132743 ± 28.2 |
PK parameter AUClast for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
| h*ng/mL | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Manogepix in Part-1 | 148314 ± 12.1 | 278079 ± 16.8 | 257783 ± 30.5 | 407819 ± 12.6 |
PK parameter AUC (0 - ∞) for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects
| h*ng/mL | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Manogepix in Part-1 | 156539 ± 14.4 | 296639 ± 17.7 | 266920 ± 33.4 | 440974 ± 9.7 |
PK parameter Cmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7
| ng/mL | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-2 | 14665 ± 17.1 | 16459 ± 7.6 |
PK parameter Tmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7
| hour | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) |
|---|---|---|
| Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-2 | 2.90 (2.87 to 2.97) | 3.50 (2.00 to 6.00) |
PK parameter AUCtau after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7
| h*ng/mL | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) |
|---|---|---|
| Area Under the Concentration-time Curve at Steady State Over the Dosing Interval Tau (AUCtau) of Manogepix in Part-2 | 224722 ± 24.2 | 258780 ± 8.4 |
The fraction of unbound manogepix has been assessed after single dose administration (oral / IV)
| percentage | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) |
|---|---|---|---|---|
| Fraction of Unbound Manogepix in Plasma in Part 1 | 0.109 ± 11.4 | 0.105 ± 22.3 | 0.192 ± 27.1 | 0.226 ± 8.2 |
A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug
| Participants | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) |
|---|---|---|---|---|---|
| Any study drug-related TEAE | 5 | 3 | 0 | 1 | 0 |
| Any treatment-emergent serious adverse event (SAE) | 0 | 0 | 0 | 0 | 0 |
| Any study drug-related TEAE leading to treatment discontinuation | 0 | 0 | 0 | 0 | 0 |
| None TEAE | 1 | 3 | 6 | 5 | 8 |
A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug
| Participants | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) |
|---|---|---|---|
| Any study drug-related TEAE not leading to treatment discontinuation | 4 | 7 | 2 |
| Any study drug-related TEAE leading to treatment discontinuation | 1 | 0 | 0 |
| Any treatment-emergent SAE | 0 | 0 | 0 |
| None TEAE | 3 | 1 | 2 |
Collected over Overall up to 42 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-dose Part -1 (Cohort 1, Oral 400 mg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Single-dose Part -1 (Cohort 1, Oral 800 mg) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Single-dose Part-1 (Cohort 2, IV 600 mg) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Single-dose Part-1 (Cohort 2, IV 1000 mg) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Single-dose Part-1 (Placebo) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Multiple-dose Part-2 (Placebo) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 3/6 | 1/6 | 0/6 | 0/6 | 0/8 | 0/8 | 5/8 | 0/4 |
| NauseaGastrointestinal disorders | 2/6 | 2/6 | 0/6 | 0/6 | 0/8 | 0/8 | 5/8 | 1/4 |
| LethargyNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 3/8 | 1/8 | 1/4 |
| Haemoglobin decreasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/8 | 0/8 | 1/4 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/8 | 2/8 | 1/4 |
| Abdominal distensionGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/8 | 2/8 | 0/4 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/8 | 0/8 | 1/4 |
| RegurgitationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/8 | 2/8 | 1/4 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/8 | 2/8 | 1/4 |
| Creatinine renal clearance decreasedInvestigations | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 | 0/8 | 1/8 | 0/4 |
Demographics and baseline characteristics (Safety set)
| Age, Continuous(years) | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.5 ± 5.75 | 32.3 ± 3.83 | 32.0 ± 7.13 | 38.8 ± 5.00 | 33.4 ± 5.10 | 31.1 ± 5.91 | 33.9 ± 6.38 | 29.5 ± 6.14 | 33.2 ± 5.84 |
| Sex: Female, Male(Participants) | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 1 | 0 | 0 | 2 | 1 | 9 |
| Male | 4 | 4 | 5 | 5 | 8 | 8 | 6 | 3 | 43 |
| Race/Ethnicity, Customized(Participants) | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 6 | 8 | 8 | 8 | 4 | 52 |
| Height (cm)(Cm) | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 166.8 ± 8.84 | 160.7 ± 10.67 | 168.2 ± 6.11 | 162.3 ± 4.97 | 171.3 ± 4.37 | 166.9 ± 7.59 | 172.9 ± 7.70 | 168.5 ± 7.00 | 167.5 ± 7.88 |
| Weight (kg)(Kg) | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.30 ± 8.26 | 62.00 ± 10.71 | 67.97 ± 9.14 | 65.28 ± 6.51 | 71.53 ± 8.84 | 65.13 ± 6.73 | 66.88 ± 8.69 | 60.70 ± 6.73 | 65.70 ± 8.45 |
| BMI (kg/m2)(Kg/m2) | Single-dose Part -1 (Cohort 1, Oral 400 mg) | Single-dose Part -1 (Cohort 1, Oral 800 mg) | Single-dose Part-1 (Cohort 2, IV 600 mg) | Single-dose Part-1 (Cohort 2, IV 1000 mg) | Single-dose Part-1 (Placebo) | Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg) | Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg) | Multiple-dose Part-2 (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 22.32 ± 1.60 | 23.87 ± 1.72 | 24.05 ± 3.05 | 24.82 ± 2.90 | 24.34 ± 2.38 | 23.40 ± 2.00 | 22.31 ± 2.04 | 21.35 ± 1.10 | 23.39 ± 2.31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2025 to primary completion in Jul 2025, 3 months.
Results were first posted in Mar 2026, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fosmanogepix